How We Can Achieve Vaccine Internationalism – and Why We Need To thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewire.in Daily Mail and Mail on Sunday newspapers.
Malaria vaccine becomes first to achieve WHO-specified 75 per cent efficacy goal
Vaccine candidate potential for large-scale manufacturing and low-cost supply
Researchers from the University of Oxford and their partners have reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77 per cent over 12-months of follow-up.
In their findings, posted on SSRN/Preprints with
The Lancet, they noted that they were the first to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75 per cent efficacy.
“These new results support our high expectations for the potential of this vaccine, which we believe is the first to reach the WHO’s goal of a vaccine for malaria with at least 75 per cent efficacy,” said Prof. Adrian Hill, Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford.
Published: Apr 23, 2021
Vaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted in Africa
Novavax Matrix-M™ adjuvant used in combination with University of Oxford malaria vaccine candidate, R21, and developed in collaboration with Serum Institute of India
Phase 3 clinical trial to evaluate safety and efficacy begun in 4,800 participants aged 5-36 months
GAITHERSBURG, Md., April 23, 2021 /PRNewswire/
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax Matrix-M™ adjuvant and is licensed to Serum Institute of India (SII). Published online in
E-Mail
Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with
The Lancet) they note that they are the first to meet the World Health Organization s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
The authors report (in findings in press with
The Lancet) from a Phase IIb randomised, controlled, double-blind trial conducted at the Clinical Research Unit of Nanoro (CRUN) / Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso. 450 participants, aged 5-17 months, were recruited from the catchment area of Nanoro, covering 24 villages and an approximate population of 65,000 people.
On our radar
A cry for help from Darfur
Sudan’s West Darfur State appealed this week for urgent help from the federal government to tackle the humanitarian fallout from clashes earlier this month between Arab Rizeigat and non-Arab Masalit communities in the city of El Geneina that left over 144 people dead and hundreds of thousands homeless. The state’s governor said his administration was unable to cope with the scale of the displacement. Khartoum has struggled to bring peace to Darfur. The violence in El Geneina was reportedly instigated by its own Rapid Support Forces, drawn largely from the former Janjaweed militia responsible for war crimes in the region in the 2000s. The RSF, which recruits heavily from the Rizeigat, is led by a key member of the transitional government, which gives the military immunity for previous and current crimes. That’s one reason why the region’s most powerful insurgent group has refused to sign a peace deal with Khartoum. In its Jebel Marra